SETTING: Queen Elizabeth Central Hospital, Blantyre, and Zomba Central Hospital, Zomba, Malawi. OBJECTIVE: To follow-up human immunodeficiency virus (HIV) seropositive and HIV-seronegative patients with smear-negative pulmonary tuberculosis (PTB) and pleural TB who had completed treatment with two different regimens in Blantyre and Zomba, and to assess rates of mortality and recurrent TB. DESIGN: Patients with smear-negative and pleural TB who had completed 8 months ambulatory treatment in Blantyre or 12 months standard treatment in Zomba and who were smear and culture negative for acid-fast bacilli at the completion of treatment were actively followed every 4 months for a total of 20 months. RESULTS: Of 248 patients, 150 with smear-negative PTB and 98 with pleural TB, who completed treatment and were enrolled, 205 (83%) were HIV-positive. At 20 months, 145 (58%) patients were alive, 85 (34%) had died and 18 (7%) had transferred out of the district. The mortality rate was 25.7 per 100 person-years, with increased rates strongly associated with HIV infection and age >45 years. Forty-nine patients developed recurrent TB. The recurrence rate of TB was 16.1 per 100 person-years, with increased rates strongly associated with HIV infection, having smear-negative PTB and having received 'standard treatment'. CONCLUSION: High rates of mortality and recurrent TB were found in patients with smear-negative PTB and pleural effusion during 20 months of follow-up. TB programmes in sub-Saharan Africa must consider appropriate interventions, such as co-trimoxazole and secondary isoniazid prophylaxis, to reduce these adverse outcomes.
SETTING: Queen Elizabeth Central Hospital, Blantyre, and Zomba Central Hospital, Zomba, Malawi. OBJECTIVE: To follow-up human immunodeficiency virus (HIV) seropositive and HIV-seronegative patients with smear-negative pulmonary tuberculosis (PTB) and pleural TB who had completed treatment with two different regimens in Blantyre and Zomba, and to assess rates of mortality and recurrent TB. DESIGN:Patients with smear-negative and pleural TB who had completed 8 months ambulatory treatment in Blantyre or 12 months standard treatment in Zomba and who were smear and culture negative for acid-fast bacilli at the completion of treatment were actively followed every 4 months for a total of 20 months. RESULTS: Of 248 patients, 150 with smear-negative PTB and 98 with pleural TB, who completed treatment and were enrolled, 205 (83%) were HIV-positive. At 20 months, 145 (58%) patients were alive, 85 (34%) had died and 18 (7%) had transferred out of the district. The mortality rate was 25.7 per 100 person-years, with increased rates strongly associated with HIV infection and age >45 years. Forty-nine patients developed recurrent TB. The recurrence rate of TB was 16.1 per 100 person-years, with increased rates strongly associated with HIV infection, having smear-negative PTB and having received 'standard treatment'. CONCLUSION: High rates of mortality and recurrent TB were found in patients with smear-negative PTB and pleural effusion during 20 months of follow-up. TB programmes in sub-Saharan Africa must consider appropriate interventions, such as co-trimoxazole and secondary isoniazid prophylaxis, to reduce these adverse outcomes.
Authors: Olivier Koole; Sopheak Thai; Kim Eam Khun; Reaksmey Pe; Johan van Griensven; Ludwig Apers; Jef Van den Ende; Tan Eang Mao; Lutgarde Lynen Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Conor D Tweed; Angela M Crook; Rodney Dawson; Andreas H Diacon; Timothy D McHugh; Carl M Mendel; Sarah K Meredith; Lerato Mohapi; Michael E Murphy; Andrew J Nunn; Patrick P J Phillips; Kasha P Singh; Melvin Spigelman; Stephen H Gillespie Journal: BMC Pulm Med Date: 2019-08-14 Impact factor: 3.317
Authors: Mecky Matee; Lillian Mtei; Tarja Lounasvaara; Wendy Wieland-Alter; Richard Waddell; Johnson Lyimo; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn Journal: BMC Public Health Date: 2008-02-21 Impact factor: 3.295
Authors: Lydia Nakiyingi; Bareng A S Nonyane; Willy Ssengooba; Bruce J Kirenga; Damalie Nakanjako; Gloria Lubega; Pauline Byakika-Kibwika; Moses L Joloba; Jerry J Ellner; Susan E Dorman; Harriet Mayanja-Kizza; Yukari C Manabe Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240